A detailed history of Franklin Resources Inc transactions in Argenx Se stock. As of the latest transaction made, Franklin Resources Inc holds 134,018 shares of ARGX stock, worth $84.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
134,018
Previous 134,018 -0.0%
Holding current value
$84.2 Million
Previous $72.7 Million -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$434.22 - $551.9 $957,020 - $1.22 Million
-2,204 Reduced 1.62%
134,018 $72.7 Million
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $11 Million - $13.9 Million
-30,871 Reduced 18.48%
136,222 $58.6 Million
Q1 2024

May 13, 2024

SELL
$356.95 - $413.29 $2.55 Million - $2.95 Million
-7,133 Reduced 4.09%
167,093 $65.8 Million
Q4 2023

Feb 09, 2024

SELL
$338.91 - $506.01 $2.86 Million - $4.27 Million
-8,442 Reduced 4.62%
174,226 $66.3 Million
Q3 2023

Nov 13, 2023

SELL
$369.35 - $548.43 $23.5 Million - $34.9 Million
-63,643 Reduced 25.84%
182,668 $89.8 Million
Q2 2023

Aug 11, 2023

SELL
$360.14 - $422.58 $132,531 - $155,509
-368 Reduced 0.15%
246,311 $96 Million
Q1 2023

May 12, 2023

BUY
$334.23 - $403.65 $11.9 Million - $14.4 Million
35,574 Added 16.85%
246,679 $91.9 Million
Q4 2022

Feb 10, 2023

SELL
$342.17 - $402.31 $89,306 - $105,002
-261 Reduced 0.12%
211,105 $80 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $13.5 Million - $15.5 Million
-39,292 Reduced 15.68%
211,366 $74.6 Million
Q2 2022

Aug 11, 2022

SELL
$269.58 - $378.88 $163,904 - $230,359
-608 Reduced 0.24%
250,658 $95 Million
Q1 2022

May 13, 2022

BUY
$254.45 - $351.06 $29.5 Million - $40.7 Million
115,982 Added 85.73%
251,266 $79.2 Million
Q4 2021

Feb 11, 2022

SELL
$272.01 - $353.03 $2,992 - $3,883
-11 Reduced 0.01%
135,284 $47.4 Million
Q3 2021

Nov 12, 2021

BUY
$295.0 - $350.58 $146,910 - $174,588
498 Added 0.37%
135,295 $40.9 Million
Q2 2021

Aug 13, 2021

BUY
$257.11 - $319.92 $2.98 Million - $3.7 Million
11,574 Added 9.39%
134,797 $40.6 Million
Q1 2021

May 13, 2021

SELL
$268.3 - $380.31 $22.2 Million - $31.5 Million
-82,714 Reduced 40.16%
123,223 $33.9 Million
Q4 2020

Feb 10, 2021

SELL
$248.13 - $308.36 $4.06 Million - $5.05 Million
-16,381 Reduced 7.37%
205,937 $60.6 Million
Q3 2020

Nov 12, 2020

SELL
$215.51 - $272.51 $72.5 Million - $91.7 Million
-336,468 Reduced 60.21%
222,318 $58.4 Million
Q2 2020

Aug 13, 2020

SELL
$127.44 - $232.72 $2 Million - $3.65 Million
-15,669 Reduced 2.73%
558,786 $145 Million
Q1 2020

May 13, 2020

SELL
$108.83 - $165.23 $5.39 Million - $8.18 Million
-49,513 Reduced 7.94%
574,455 $75.7 Million
Q4 2019

Feb 12, 2020

BUY
$106.59 - $164.21 $11.1 Million - $17.2 Million
104,441 Added 20.1%
623,968 $100 Million
Q3 2019

Nov 14, 2019

BUY
$113.31 - $150.51 $25,268 - $33,563
223 Added 0.04%
519,527 $59.2 Million
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $3.34 Million - $4.11 Million
29,001 Added 5.91%
519,304 $73.5 Million
Q1 2019

May 14, 2019

SELL
$98.85 - $134.59 $3.75 Million - $5.1 Million
-37,913 Reduced 7.18%
490,303 $61.2 Million
Q4 2018

Feb 12, 2019

SELL
$63.81 - $109.82 $4.63 Million - $7.96 Million
-72,505 Reduced 12.07%
528,216 $50.7 Million
Q3 2018

Nov 13, 2018

BUY
$75.5 - $96.63 $8.14 Million - $10.4 Million
107,800 Added 21.87%
600,721 $45.6 Million
Q2 2018

Aug 14, 2018

BUY
$74.84 - $100.16 $3.02 Million - $4.04 Million
40,321 Added 8.91%
492,921 $40.8 Million
Q1 2018

May 10, 2018

SELL
$56.95 - $85.19 $284,750 - $425,950
-5,000 Reduced 1.09%
452,600 $36.4 Million
Q4 2017

Feb 14, 2018

BUY
$22.57 - $63.56 $2.43 Million - $6.84 Million
107,600 Added 30.74%
457,600 $28.9 Million
Q3 2017

Nov 13, 2017

BUY
$19.81 - $22.61 $6.93 Million - $7.91 Million
350,000
350,000 $7.85 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.